Stem cell therapy for interstitial cystitis/bladder pain syndrome.

Area of Science:

• Regenerative Medicine
• Urology
• Cell Biology

Background:

• Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition with limited effective treatments, often necessitating invasive surgery.
• Current therapies targeting bladder inflammation and urothelial dysfunction provide insufficient long-term relief for many patients.

Purpose of the Study:

• To evaluate the safety and potential efficacy of stem cell therapy as a novel treatment for IC/BPS.
• To explore stem cell therapy as an alternative to major surgery for bladder preservation in IC/BPS patients.

Main Methods:

• A phase 1 clinical trial involving cystoscopic submucosal injection of human embryonic stem cell-derived mesenchymal stem cells into three patients with Hunner-type IC.
• Monitoring of safety and therapeutic response over a 12-month follow-up period, with extended long-term observation up to 3 years.

Main Results:

• No safety concerns were reported during the follow-up period.
• All patients experienced significant pain improvement within one month post-injection.
• While therapeutic responses varied, overall pain management improved, potentially reducing the need for surgical intervention.

Conclusions:

• Stem cell therapy presents a potential therapeutic avenue for managing IC/BPS, demonstrating safety and preliminary efficacy in pain reduction.
• Further clinical trials, including ongoing phase 1/2a studies, are crucial to fully elucidate the clinical application and long-term benefits of stem cell therapy for IC/BPS.